Author

Z. Balazs

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

M. Krauthammer· 2 shared A. Aloia· 1 shared A. Bileck· 1 shared A. Dzung· 1 shared A. Irmisch· 1 shared A. Kolz· 1 shared A. Leitner· 1 shared A. Othman· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Krauthammer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Memory Th1 cells modulate heterologous diseases through innate function

N. Rakebrandt, N. Yassini, A. Kolz, M. Schorer, K. Lambert, C. Rauld, Z. Balazs, M. Krauthammer, J. Carballido, A. Peters, N. Joller

This study identifies memory Th1 cells that can respond rapidly to unrelated pathogens or diseases through TCR-independent IFN-γ production, influencing susceptibility to heterologous challenges.

bioRxiv · Mar 22, 2023 · PreprintImmunology

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma

O. M. Eichhoff, C. I. Stoffel, J. Kaesler, L. Briker, P. Turko, G. Karsai, N. Zila, V. Paulitschke, P. F. Cheng, A. Leitner, A. Bileck, N. Zamboni, A. Irmisch, Z. Balazs, A. Tastanova, , M. Levesque

The paper identifies ROS induction as a strategy to target MEK-inhibitor resistant NRAS-mutated melanoma cells by exploiting their quiescent metabolic state and elevated baseline ROS levels.

bioRxiv · Oct 19, 2022 · PreprintCancer Biology